Multicenter phase 2 trial of high-dose aumolertinib for untreated EGFR-variant non-small cell lung cancer with brain metastases

The phase 2 ACHIEVE trial, at 10 centers in China, evaluated aumolertinib 165 mg orally once daily for patients with previously untreated EGFR-variant metastatic non-small cell lung cancer and brain metastases. In this trial of 63 patients, the 12-month progression-free survival rate was 62.1%. The safety profile was manageable. The authors conclude that high-dose aumolertinib was associated with long-term survival benefit among patients with untreated EGFR-variant NSCLC and brain metastases